Plain-English translation of NCT07445438 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are testing a new multi-omics platform — a sophisticated laboratory tool that can analyze blood and tissue samples in multiple ways to better diagnose blood cancers. This study will use samples from patients who already need diagnostic testing or who have previously had samples stored for research, helping doctors understand which patients have blood cancers and what type they have.
Current methods for diagnosing blood cancers can sometimes be limited or take time. This new testing platform may help doctors identify blood cancers faster and more accurately, which could lead to better treatment decisions and outcomes for patients.
You likely qualify if…
You likely don't qualify if…
If you are newly diagnosed or suspected of having a blood cancer, your doctor will collect samples during your routine diagnostic appointment — this may include blood draws, bone marrow samples, or tissue biopsies you would likely need anyway. If you have previously had samples stored for research, researchers will use those existing samples with your permission. The samples are sent to a laboratory where the new testing tool analyzes them to help confirm or identify your condition.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
Italy
Sponsor
Azienda Ospedaliero-Universitaria di Parma
Enrollment target
~1,040 participants
Started
March 2025
Primary completion
March 2030
Age range
2 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Giovanni Roti, Associate Professor
Azienda Ospedaliero-Universitaria di Parma
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.